|
High Throughput 3D Cell Assay for Metastatic Prostate Cancer
|
1R41CA165463-01A1
|
$199,134
|
TAKAYAMA, SHUICHI
|
3D BIOMATRIX, INC.
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-04
|
$1,917,582
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-39S4
|
$3,757,417
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S5
|
$249,999
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S6
|
$249,999
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S7
|
$75,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Targeting Cancer Cells with Functionalized Nanoparticle Libraries
|
5R21CA157366-02
|
$176,055
|
LEVY, MATTHEW
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Genomics and Predictive Modeling of Prostate Cancer Heath Disparity
|
5U01CA158431-02
|
$335,248
|
Ostrer, Harry
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-38
|
$101,749
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Skp2 in androgen-dependent proliferation of prostate cancer cells
|
5R01CA127901-04
|
$300,705
|
ZHU, LIANG
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Community Clinical Oncology Program
|
5U10CA037422-25
|
$4,499,349
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-36S1
|
$172,284
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-36
|
$12,915,055
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RTOG Biospecimen Repository
|
5U24CA114734-07
|
$500,745
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
|
5U01CA141497-04
|
$671,170
|
ITTMANN, MICHAEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Bioflavonoid Effects on EGF Signaling and Cell Cycle Pathways in Prostate Cancer
|
5R01CA128932-04
|
$308,958
|
MARKAVERICH, BARRY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S1
|
$41,433
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S2
|
$75,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-06
|
$2,934,758
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
DNA Repair and Replication Re-start in vivo
|
5R01CA085777-09
|
$291,579
|
Rosenberg, Susan
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
5R01CA058093-19
|
$261,747
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
METABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCER
|
1U01CA167234-01
|
$338,240
|
Sreekumar, Arun
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integrative Metabolomics of Prostate Cancer Progression
|
5R01CA133458-05
|
$314,511
|
Sreekumar, Arun
|
BAYLOR COLLEGE OF MEDICINE
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
3R00CA125937-05S2
|
$56,448
|
Xin, Li
|
BAYLOR COLLEGE OF MEDICINE
|
|
MECHANISMS OF SRC ACTIVATION AND ITS ROLE IN LATENT BONE METASTASIS OF BREAST AND
|
5R00CA151293-03
|
$241,529
|
Zhang, Xiang
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-14
|
$95,411
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Molecular basis of androgen receptor mediated gene transcriptional repression
|
1K99CA166507-01
|
$134,946
|
Cai, Changmeng
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Androgen Receptor Regulation by Phosphorylation
|
5R00CA135592-04
|
$241,529
|
Chen, Shaoyong
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Platform for Cancer Biomarker Validation: Image Fusion Using NIR Fluorescence
|
5R01CA134493-04
|
$688,070
|
Frangioni, John
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Stromal Regulation of Bone Metastasis
|
5U54CA163191-02
|
$902,456
|
KALLURI, RAGHU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
PTEN and ontogenesis and tumor suppression
|
5R01CA082328-15
|
$340,612
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of POZ-zinc finger proteins in tumorigenesis.
|
5R01CA102142-08
|
$330,937
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A metabolic role for PML in tumor suppression
|
5R01CA142780-03
|
$350,219
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressor Phosphatases For Cancer Therapy
|
5U01CA141496-04
|
$801,051
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
|
5U01CA113913-08
|
$689,700
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting prostate cancer stem cells to delay prostate cancer progression
|
5R21CA153355-02
|
$227,070
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S1
|
$300,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S2
|
$139,989
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-03
|
$310,336
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
Combination Therapies for Cancer Treatment
|
5R01CA049248-22
|
$328,240
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
Mechanisms of Action and Signaling by Steroid Hormone Antagonists
|
5R01CA101992-08
|
$252,463
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Targeting Endoplasmic Reticulum Stress Response for Cancer Therapy
|
7R01CA152312-02
|
$368,100
|
AKTAS, BERTAL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Modeling PCa Bone Metastasis: Dual Role of E-selectin Ligands and Integrins
|
5F32CA144219-02
|
$60,434
|
Barthel, Steven
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
3U10CA031946-31S1
|
$114,228
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-27S1
|
$405,901
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-31
|
$7,759,618
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-28
|
$2,286,202
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Obesity increased cancer risk by NKT cell depletion (PQ1)
|
1R21CA170194-01
|
$227,371
|
EXLEY, MARK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|